STRUCTURALLY ALTERED CAPSULAR POLYSACCHARIDES PRODUCED BY MUTANT BACTERIA

Inventors: Roger G. Kern, Pasadena; Gene R. Petersen, Pomona; Gil F. Richards, Duarte, all of Calif.

Assignee: California Institute of Technology, Jet Propulsion Laboratory, Pasadena, Calif.

Appl. No.: 258,386
Filed: Jun. 10, 1994

Related U.S. Application Data

References Cited
U.S. PATENT DOCUMENTS
5,330,903 7/1994 Kern et al. 435/101

Primary Examiner—Ronald W. Griffin
Attorney, Agent, or Firm—Graham & James

ABSTRACT
Structurally altered capsular polysaccharides are produced by mutant bacteria. These polysaccharides are isolated by selecting a wild type bacterial strain and a phage producing degradative enzymes that have substrate specificity for the capsular polysaccharides produced by the wild type bacteria. Phage-resistant mutants producing capsular polysaccharides are selected and the structurally altered capsular polysaccharide is isolated therefrom.

8 Claims, No Drawings
STRUCTURALLY ALTERED CAPSULAR POLYSACCHARIDES PRODUCED BY MUTANT BACTERIA

The invention described herein was made in the performance of work under a NASA contract, and is subject to the provisions of Public Law 96-517 (35 U.S.C. § 202) in which the Contractor has elected to retain title.

This application is divisional of U.S. Ser. No. 07/799,419 filed Nov. 27, 1991, now U.S. Pat. No. 5,330,903.

This invention relates to novel and useful complex polysaccharides and methods for producing them. More particularly, this invention relates to structurally altered capsular polysaccharides produced by bacterial mutants.

BACKGROUND OF THE INVENTION

Complex polysaccharides have a variety of industrial applications. Generally these molecules alter the physical properties—including viscosity and rheology—of fluid media in which they are suspended. Accordingly, complex polysaccharides are used as thickeners in the food industry, for suspending waste fragments in drilling or cutting operations, and as water soluble lubricants. Baird et al., "Industrial Applications Of Some New Microbial Polysaccharides," Biotechnology, November 1983, pp. 778–83. For similar reasons, complex polysaccharides are also used to reduce turbulence of fluid flow in pipelines and other containers. J. W. Hoyt, Drag Reduction In Polysaccharide Solutions, Trends In Biotechnology, 3, 17–20 (1985). The physico-chemical basis for these effects is not understood, id. although correlations between drag reduction and the extensional viscosity of polysaccharides have been reported. G. R. Petersen et al., "Rheologically Interesting Polysaccharides From Yeasts", Appl. Biochem. Biotech., 20/21, 845–67 (1989).

Because the basis for these useful properties of complex polysaccharides is not understood, the identification of useful complex polysaccharides requires screening of candidate polymers. Accordingly, it is desirable to develop methods for producing new candidate complex polysaccharides for evaluation.

SUMMARY OF THE INVENTION

Structurally altered capsular polysaccharides are produced by mutant bacteria. These polysaccharides are isolated by selecting a wild type bacterial strain and a phage producing degradative enzymes that have substrate specificity for the capsular polysaccharides produced by the wild type bacteria. Phage-resistant mutants producing capsular polysaccharides are selected and the structurally altered capsular polysaccharide is isolated therefrom.

DETAILED DESCRIPTION OF THE INVENTION

The cells of many bacterial species—specifically, gram positive bacteria—are surrounded by a glyocalyx also referred to as a capsular polysaccharide ("CPS") several hundred nanometers in thickness. The glyocalyx consists of a complex polysaccharide polymer that appears to be species specific. H. Geyer et al. "Degradation Of Bacterial Surface Carbohydrates By Virus-Associated Enzymes", Pure And Applied Chemistry, 55, pp. 637–53 (1983). Hence bacteria have proved to be an important source of complex polysaccharides. Baird et al. (1983). Bacteria are an especially desirable source of polysaccharides because of the purity and uniformity of the product.

Bacteriophage are viruses that infect bacteria. The viruses that infect bacteria encapsulated by a glyocalyx are specially adapted to penetrate the polysaccharide barrier. The tail fibers or spikes by which these viruses are seen to attach to bacteria contain enzymes—generally referred to as endoglucanases or endopolysaccharases—that degrade the glyocalyx. These enzymes exhibit a high degree of substrate specificity. Geyer et al, supra at pp. 38–39.

According to the present invention, a strain of encapsulated bacteria and the specific phage which infects it are employed. The selected bacteria are optionally exposed to a mutagenic agent. Examples of useful mutagenic agents include radiation and chemical mutagens, such as nitrosoguanidine. The mutagenized bacterial cells are grown to a desired density, and then screened for resistance to phage that specifically degrade the glyocalyx of the wild type strain. Surviving bacteria are likely to have a glyocalyx with altered chemical structure. The CPS of the selected bacterial strains is harvested with enzymes derived from phage. The isolated CPS is purified by known techniques and degraded to oligomer by further treatment with phage enzymes.

In one embodiment of the present invention, we employed a strain Klebsiella pneumoniae that produces a capsular polysaccharide known as K63, and a phage ("K63 phage") that specifically degrades the same polysaccharide. We obtained Klebsiella pneumoniae strain 5845/52 from the World Health Organization. This strain produces the K63 capsular protein. The K63 CPS is a straight chain heteropolymer of fucose, galacturonic acid and galactose, linked, in that order by α 1–3 glycosidic linkages. The K63 phage enzymatically hydrolyzes the α 1–3 linkage between the galactose and fucose monomers. Both the nature of the CPS polymer and the mode of action of the K63 phage enzyme are representative, and support the general applicability of our method.

We selected mutants for further study that were either spontaneously generated or were induced by exposure to the mutagenic agents nitrosoguanidine or ultraviolet radiation. J. H. Miller, Experiments In Molecular Genetics (1972). Following treatment to induce mutation, cells were grown on DIFCO Nutrient Broth, supplemented with 1% glucose, at 30° C., while rotated at 150 rpm. Cells were grown to early stationary phase (OD590 of approximately 3.5). Calcium chloride (0.1M) was added to stabilize the CPS matrix.

The fresh stationary phase culture, less than 2 hours old, contained approximately 2.5 x 109 viable cells/ml. Phage 63 was added at a concentration sufficient to achieve a multiplicity of infection ("MOI") of between one and five. The culture was incubated at room temperature for about 10 minutes to permit phage to attach to the bacterial cells. The infected culture was then diluted 10 fold into fresh glucose supplemented nutrient broth and grown overnight to stationary phase.

Phage resistant mutants were isolated as single colonies on petri dishes after streaking with the overnight culture of infected bacteria. Resistant colonies that did not form plaques were selected. Phage resistance of the selected colonies was confirmed by administration of a
phage resistance when compared with wild type
bacteria.

Mutants whose phage resistance was due to altered
CPS were selected from among those phage resistant
mutants already identified. The phage resistant colonies
were grown for 5 to 7 days so that mucoid (cp~ pro-
sidered measurements that differed by less than
mutants already identified. The phage resistant colonies
were retested for phage resistance as before. Mucoid mutants that remained phage
resistant were assumed to have altered CPS. Non-
umucoid phage resistant mutants were assumed to be
resistant for other reasons, for example, lacking virus
receptor sites. Approximately 90% of the 5845/82
phage resistant mutants have altered CPS by this cri-
etion.

In order to test the capacity of the altered CPS from
mutant cells to affect rheological properties of aqueous
media we partially purified the CPS. The cultured
mutant bacterial cells, like those produced by large-

scale industrial fermentations, is resistant to high speed
centrifugation. We succeeded in achieving substantial
purification of the altered CPS using a concentrated
extract of phage enzymes.

A concentrated mixture of CPS specific enzyme and
phage fragments was prepared by preparing a phage
lysate from stationary phase cultures, and concentrating
the lysate 80 fold with an AMICON hollow fiber filter
(HF110), followed by dialysis to remove low molecular
weight substances. The final concentration factor was
39. This material showed a 24-fold enhancement in
enzymatic activity as determined by a reducing end
sugar assay, as compared with crude phage lysate.

Phage/enzyme concentrate was added in small quan-
tities—1 ml/1iter—to cultures of mutant bacterial cells.

This results in a rapid and dramatic reduction (>100
fold) in the viscosity of the culture media. Altered CPS
was thereafter separated from the bacterial cells by low
speed centrifugation at 20° C. Immediately after centrifu-
gation, the supernatant was precipitated by the addi-
tion of 4 volumes of isopropanol at —20° C. We have
also used ethanol in place of cold isopropanol. The
resulting precipitate was rehydrated and extensively
dialyzed against deionized water.

The CPS polymer obtained from wild-type K63 bac-
teria had an apparent molecular weight of 3.5X106
daltons. Digestion of this material with phage 63 en-
zyme reproducibly yielded a homogeneous mono-dis-
perss polysaccharide with a molecular weight of
9.0X105 daltons.

We measured the drag reduction produced by undi-
gested CPS harvested from wild type and mutant K63
bacteria using a turbulent flow rheometer fabricated
dering to the design of Hoyt [J. W. Hoyt, Polymer
Lett., 9, 851—62 (1971); J. W. Hoyt, "The solution
Properties Of natural Polymers", The Chemical Society
Spezial Publication, No. 23, (London) pp. 86—91 (1968)]
modified by altering pipe diameter to operate at a fixed
Reynolds number of 16,500. The drag reduction was
calculated:

\[
\text{Drag Reduction} = \frac{100 \times (PD_{solvent} - PD_{solution})}{PD_{solvent}}
\]

Where PD_{solvent} and PD_{solution} are the pressure
differences in the solvent and solution, respectively, mea-
sured from a strip chart recording of pressures taken at
two points, 12.7 cm apart, along a 1 mm pipe. Between
two sample runs, the rheometer was rinsed with tap water
until the baseline returned to normal. Sample size was
100 ml and all measurements were made with water as
the solvent. Sample observations were normalized
(wt/ppm or mg/l) typically 100—500 wt/ppm. Our ob-
servations were reproducible to within 1—2%. We con-
sidered measurements that differed by less than 5% to
be equivalent.

Our observations of drag reduction coefficients for
wild type and mutant CPS (from 8 mutant strains) are
summarized in Table 1. Mutant strains 1, 2 and 5 were
spontaneous mutants, while strains 3, 4, 5, 6, and 8 were
induced by nitrosoguanidine. All mutants showed a
decrease in pyruvulation while altered NMR spectra
have been detected only in the spontaneous mutants.

Our results show a 10% improvement in drag reduction
in the CPS from mutant bacteria. Furthermore, as also
shown in Table 1, CPS from mutant bacteria is more
resistant to mechanical shearing as determined by re-
peated observations of drag reduction with a rheome-
eter.

<table>
<thead>
<tr>
<th>STRAIN</th>
<th>% DRAG REDUCTION</th>
<th>% SHEAR STABILITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>K63 wt</td>
<td>55.9</td>
<td>84.9</td>
</tr>
<tr>
<td>K63-JPL1</td>
<td>63.7</td>
<td>95.6</td>
</tr>
<tr>
<td>K63-JPL2</td>
<td>66.7</td>
<td>95.6</td>
</tr>
<tr>
<td>K63-JPL3</td>
<td>67.0</td>
<td>99.4</td>
</tr>
<tr>
<td>K63-JPL4</td>
<td>67.6</td>
<td>98.2</td>
</tr>
<tr>
<td>K63-JPL5</td>
<td>70.0</td>
<td>99.4</td>
</tr>
<tr>
<td>K63-JPL6</td>
<td>67.6</td>
<td>95.7</td>
</tr>
<tr>
<td>K63-JPL8</td>
<td>67.2</td>
<td>99.7</td>
</tr>
</tbody>
</table>

While we have presented a number of embodiments
of this invention by way of examples, it is apparent
that our basic construction can be altered to provide other
embodiments that also employ our invention. The scope
of our invention is defined by the scope of the claims,
rather than by the examples, which are only intended to
be illustrative.

We claim:

1. An isolated altered capsular polysaccharide pro-
duced by the steps of:
   (a) providing a wild type bacterial strain that pro-
duces a capsular polysaccharide and a bacterio-
phage that degrades at least one capsular polysac-
charide produced by the wild type bacterial strain;
   (b) selecting phage resistant mutants of the bacterial
strain that produce a capsular polysaccharide;
   (c) propagating mutants to obtain a culture thereof;
   and
   (d) harvesting the altered capsular polysaccharides of
the mutants.

2. The isolated altered capsular polysaccharide of
claim 1 wherein the wild type bacterial strain is
Klebsiella pneumoniae 5845/82.

3. The isolated altered capsular polysaccharide of
claim 1 wherein the capsular polysaccharide is K63.

4. The isolated altered capsular polysaccharide of
claim 1 wherein the step of selecting mutants optionally
comprises the step of treating the selected wild type
bacterial strain with a mutagenic agent.
5. The isolated altered capsular polysaccharide of claim 1 wherein the mutagenic agent is radiation or nitrosoguanidine.

6. The isolated altered capsular polysaccharide of claim 1 wherein the step of selecting mutants further comprises the steps of:
   (a) exposing bacterial cultures to degradative phage enzymes with substrate specificity for the capsular polysaccharide of the wild type bacterial strain; and
   (b) selecting those cultures that produce a capsular polysaccharide but survive exposure to the degradative phage enzyme of step (a) above.

7. The isolated altered capsular polysaccharide of claim 1 wherein the step of harvesting further comprises the steps of:
   (a) treating the mutant bacterial cultures with phage enzyme;
   (b) separating the capsular polysaccharide from other components of the treated mutant bacteria by centrifugation; and
   (c) precipitating the supernatant obtained in step (b) above with cold isopropanol or cold ethanol.

8. The isolated altered capsular polysaccharide of claim 7, wherein the step of separating further comprises the step of digesting the precipitate with concentrated phage enzyme.

***